Back to Results

Theravance Biopharma Inc (TBPH)

Featured in High-Growth Small-Cap Stocks

Theravance Biopharma Inc. (NASDAQ: TBPH) is a healthcare company focused on developing and commercializing medicines in the United States. Its marketed product portfolio includes YUPELRI, a once-daily nebulized long-acting muscarinic antagonist used in the treatment of chronic obstructive pulmonary disease (COPD). The company is also advancing Ampreloxetine, an investigational once-daily norepinephrine reuptake inhibitor being studied in Phase 3 trials for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Theravance Biopharma has a strategic collaboration with Viatris Inc. related to the development and commercialization of revefenacin, including YUPELRI inhalation solution. Incorporated in 2013, the company is based in South San Francisco, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-TBPH
$14.78
-13.3% Downside
Fair
$17.67
3.6% Upside
Fair
Great
0.0%
November 10, 2026
16.5x
3.1x
8.5x
884.2 M
536.1 M
4.2%
49.8%
1.6
99.9%
Valuation • Fair Value

Theravance Biopharma Inc (NASDAQ-TBPH) Fair Value by Valuation Model

Review the available estimates for Theravance Biopharma Inc (NASDAQ-TBPH), including DCF Fair Value, Ben Graham Formula Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$14.78

Estimated downside of 13.3% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$16.70

Discounted cash flow valuation reference.

Ben Graham Formula Value

$11.50

Classic Ben Graham valuation formula reference.

EPV Fair Value

$16.01

Earnings power value estimate.

Comps Fair Value

$13.77

Comparable-company valuation reference.

Analyst Price Target

$17.67

Analysts imply upside of 3.6%.

How to read these valuation models

Use the 7 available valuation references for Theravance Biopharma Inc (NASDAQ-TBPH) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Theravance Biopharma Inc (NASDAQ-TBPH)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

104.3 M

Current operating scale indicator.

Revenue Forecast

83.982 M

Forward revenue estimate.

EBITDA

11.102 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Theravance Biopharma Inc (NASDAQ-TBPH) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Theravance Biopharma Inc (NASDAQ-TBPH)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.52

No elevated caution signal from this screen.

Altman Z-Score

1.6

Lower score that deserves closer risk review.

FCF / Net Income

99.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Theravance Biopharma Inc (NASDAQ-TBPH). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Theravance Biopharma Inc (NASDAQ-TBPH)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 10, 2026

Days to Earnings

49

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Theravance Biopharma Inc (NASDAQ-TBPH), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Theravance Biopharma Inc (NASDAQ-TBPH) Stock Forecast & Technical Outlook

Review Theravance Biopharma Inc (NASDAQ-TBPH) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Theravance Biopharma Inc (NASDAQ-TBPH) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Theravance Biopharma Inc (NASDAQ-TBPH) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Theravance Biopharma Inc (NASDAQ-TBPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Theravance Biopharma Inc (NASDAQ-TBPH) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Theravance Biopharma Inc (NASDAQ-TBPH) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Theravance Biopharma Inc (NASDAQ-TBPH)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Theravance Biopharma Inc (NASDAQ-TBPH) has a Hold consensus, with 0 buy, 4 hold and 0 sell recommendations in the current data set.

Buy 0
Hold 4
Sell 0
FAQ • Fast Investor Answers

Theravance Biopharma Inc (NASDAQ-TBPH) Stock FAQ

Data-supported answers about Theravance Biopharma Inc (NASDAQ-TBPH), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$14.78
Estimated downside 13.3%
Valuation Rating
Overvalued
Estimated downside of 13.3%
Analyst Target
$17.67
Implied upside 3.6%
Financial Health
Great
Current financial-health read

The current fair value estimate for Theravance Biopharma Inc (NASDAQ-TBPH) is $14.78. This implies an estimated downside of 13.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 13.3% versus the current market price.

The available analyst price target for Theravance Biopharma Inc (NASDAQ-TBPH) is $17.67. The analyst target implies estimated upside of 3.6%.

The current financial health read for Theravance Biopharma Inc (NASDAQ-TBPH) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Theravance Biopharma Inc (NASDAQ-TBPH) is November 10, 2026.

The latest available data indicates no current dividend yield for Theravance Biopharma Inc (NASDAQ-TBPH).

The current P/E ratio listed for Theravance Biopharma Inc (NASDAQ-TBPH) is 16.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Theravance Biopharma Inc is 884.2 M.

The current enterprise value listed for Theravance Biopharma Inc is 536.1 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Theravance Biopharma Inc is NASDAQ-TBPH, and the stock is listed on NASDAQ.

Theravance Biopharma Inc (NASDAQ-TBPH) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Theravance Biopharma Inc is 4.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Theravance Biopharma Inc is 49.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B